MyFinsight
Home
Blog
About
Net loss applicable
to common...
-$8,862,843
(-0.83%↓ Y/Y)
Net loss
attributable to...
-$3,056,417
(-638.26%↓ Y/Y)
Net loss
-$11,919,260
(-29.50%↓ Y/Y)
Income tax expense
(benefit)
-$107,347
(-140.62%↓ Y/Y)
Gross Product Revenue
$1,708,560
Loss before income
taxes
-$12,026,607
(-34.53%↓ Y/Y)
Revenues
$1,493,788
Grosstonet Adjustments
$214,772
Operating loss
-$11,732,074
(-33.50%↓ Y/Y)
Total other income
(expense), net
-$294,533
(-94.25%↓ Y/Y)
Gross profit
$1,001,945
Interest income
$116,691
(465.45%↑ Y/Y)
Cost of revenues
$491,843
Total operating
expenses
$12,734,019
(44.90%↑ Y/Y)
Interest expense
$231,732
(34.52%↑ Y/Y)
Amortization of deferred
financing costs
$179,492
General and
administrative
$6,149,173
(38.28%↑ Y/Y)
Stock-based compensation
general and...
$3,810,665
(40.11%↑ Y/Y)
Amortization of in-process
research and development
$1,720,312
Research and development
$1,053,869
(-35.00%↓ Y/Y)
Back
Back
Income Statement
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)
source: myfinsight.com